Résumé
The early and functional evaluation of antiangiogenic treatments in oncology is themain goal. At present, technical advances in doppler ultrasonography allow the detection of neovascularization for superficial and deep malignant tumors in order to evaluate the efficiency of new treatments. Injection of contrast agents improves the efficiency of this technique, and developments of perfusion software optimize this detection. Treatment response using dynamic contrast enhanced-ultrasonography (DCEUS) from the raw linear data can be early predicted based on the changes in the vascularization calculating perfusion parameters as maximal peak intensity, time to peak intensity, area under the curve, and slope coefficient of the curve. This technique is currently validated in 20 centerswith more than 490 patients included. The preliminary results on 400 patients confirmed that DCE-US is a sensitive and accessible tool that allows to predict earlier the response to treatment according to modifications of neovascularization before any volumic changes as per RECIST criteria.
| Titre traduit de la contribution | Where are we at with DCE-US (dynamic contrast enhancedultrasonography)? |
|---|---|
| langue originale | Français |
| Pages (de - à) | 197-201 |
| Nombre de pages | 5 |
| journal | Oncologie |
| Volume | 12 |
| Numéro de publication | 3 |
| Les DOIs | |
| état | Publié - 1 janv. 2010 |